ReviewCureus2025
Heart Rate Variability as a Predictor of Mortality in Heart Failure: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Role of Exercise in Modulating the Brain-Heart Axis in Cardiovascular Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart rate variability (HRV), a marker of autonomic function, has been proposed as a prognostic tool in heart failure (HF), but evidence remains fragmented. This meta-analysis synthesizes data on HRV's predictive value for mortality in HF. Following PRISMA guidelines, PubMed, Embase, Cochrane, and other databases (2000-2024) were systematically searched for studies assessing HRV and mortality in HF. Ten studies (n = 10,544) were included, and random-effects meta-analyses were conducted. The pooled effect size (ES) for the HRV-mortality association was significant (ES = 1.99, 95% CI: 1.36-2.61, p < 0.001), with time-domain measures (standard deviation of NN intervals (SDNN)) showing the strongest prediction (ES = 1.75, I² = 71.49%). Subgroup analyses revealed consistent effects in heart failure with reduced ejection fraction (HFrEF) (ES = 1.74) and mixed populations (ES = 1.99), though heterogeneity was high (I² = 97.67%). HRV improved risk stratification beyond ejection fraction and New York Heart Association (NYHA) class, particularly for sudden death (hazard ratio (HR): 2.1-3.2). Impaired HRV is a robust mortality predictor in HF, with SDNN being the most reliable parameter. Standardization and HRV-guided therapy trials are needed to enhance clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.